InferMed

A decade of development work at the Imperial Cancer Research Fund led to the spin-out of Infermed in 1998. The London company, headed by Andrew Newbigging, develops decision-making software to manage drug trials and improve patient treatment. Sales have grown 74% a year from £553,000 in 1999 to £1.7m in 2001, and more than 90% of them come from overseas.

This profile reflects the company at time of publication and does not reflect any changes that may have subsequently occurred. Fast Track and its sponsors do not endorse, guarantee or recommend investment in any of the companies.

Company details
Year2002
Rank71
CompanyInferMed
ActivityMedical software developer
LocationCentral London
Average 3 year sales growth74.28%
Latest sales £000s1,680
Staff40
Founded1998
Websitewww.infermed.com

If applicable:

* supplied by company † annualised figure